IDYA insider filings
IDEAYA Biosciences, Inc. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-07-09. Screen IDYA transaction legs live →
Insider transaction summary — last 90 days
No insider filings (Forms 3/4/5) for IDYA between 2026-07-10 and 2026-10-08. The table below lists the most recent filings on record.
Recent insider filings — IDEAYA Biosciences, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-07-09 | 4 | Ruiz Briseno Andres — Chief Accounting Officer | Option exercise (M): 9,550 @ $12.86 · Sale (S): 9,550 @ $40.01 · Option exercise (M): 9,550 (derivative) @ $0 | EDGAR |
| 2026-06-18 | 4 | Hampton Malcolm Garret — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2026-06-18 | 4 | Morrison Scott W — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2026-06-18 | 4 | MACKEY CATHERINE J — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2026-06-18 | 4 | Stein Jeffrey — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2026-06-18 | 4 | ROSEN TERRY J — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2026-06-18 | 4 | YARNO WENDY L — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2026-03-02 | 4 | Stein Jeffrey — Director | Purchase (P): 50,000 @ $32.96 | EDGAR |
| 2026-02-02 | 4 | Bleharski Joshua — Chief Financial Officer | Grant/award (A): 170,000 (derivative) @ $0 | EDGAR |
| 2026-02-02 | 4 | WHITE MICHAEL ANTHONY — Chief Scientific Officer | Grant/award (A): 190,000 (derivative) @ $0 | EDGAR |
| 2026-02-02 | 4 | DORMAN STUART — Chief Commercial Officer | Grant/award (A): 155,000 (derivative) @ $0 | EDGAR |
| 2026-02-02 | 4 | Snyder Douglas B. — SVP, General Counsel | Grant/award (A): 1,039 @ $16.91 · Grant/award (A): 1,041 @ $16.91 · Grant/award (A): 130,000 (derivative) @ $0 | EDGAR |
| 2026-02-02 | 4 | Ruiz Briseno Andres — See Remarks | Grant/award (A): 682 @ $23.26 · Grant/award (A): 1,253 @ $16.91 · Grant/award (A): 80,000 (derivative) @ $0 | EDGAR |
| 2026-02-02 | 4 | Hata Yujiro S — President and CEO, Director | Grant/award (A): 600,000 (derivative) @ $0 | EDGAR |
| 2026-02-02 | 4 | Beaupre Darrin — Chief Medical Officer | Grant/award (A): 175,000 (derivative) @ $0 | EDGAR |
| 2025-06-26 | 4 | Hampton Malcolm Garret — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2025-06-26 | 4 | Morrison Scott W — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2025-06-26 | 4 | MACKEY CATHERINE J — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2025-06-26 | 4 | Stein Jeffrey — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2025-06-26 | 4 | ROSEN TERRY J — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2025-06-26 | 4 | YARNO WENDY L — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2025-02-28 | 4 | DORMAN STUART — Chief Commercial Officer | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2025-02-28 | 4 | Ruiz Briseno Andres — See Remarks | Grant/award (A): 75,000 (derivative) @ $0 | EDGAR |
| 2025-02-28 | 4 | WHITE MICHAEL ANTHONY — Chief Scientific Officer | Grant/award (A): 185,000 (derivative) @ $0 | EDGAR |
| 2025-02-28 | 4 | Snyder Douglas B. — SVP, General Counsel | Grant/award (A): 33,000 (derivative) @ $0 | EDGAR |
| 2025-02-28 | 4 | Hata Yujiro S — President and CEO, Director | Grant/award (A): 600,000 (derivative) @ $0 | EDGAR |
| 2025-02-28 | 4 | Beaupre Darrin — Chief Medical Officer | Grant/award (A): 185,000 (derivative) @ $0 | EDGAR |
| 2025-02-19 | 4 | Hata Yujiro S — President and CEO, Director | Option exercise (M): 12,808 @ $19.52 · Option exercise (M): 12,808 (derivative) @ $0 | EDGAR |
| 2024-09-27 | 4 | Snyder Douglas B. — SVP, General Counsel | Grant/award (A): 140,000 (derivative) @ $0 | EDGAR |
| 2024-06-27 | 4 | Throne Jason — Chief Legal Officer | Option exercise (M): 6,424 @ $13.34 · Option exercise (M): 47,060 @ $7.01 · Option exercise (M): 6,424 (derivative) @ $0 · Option exercise (M): 47,060 (derivative) @ $0 | EDGAR |
| 2024-05-31 | 4 | Hampton Malcolm Garret — Director | Grant/award (A): 16,200 (derivative) @ $0 | EDGAR |
| 2024-05-31 | 4 | WHITE MICHAEL ANTHONY — Chief Scientific Officer | Option exercise (M): 28,500 @ $12.86 · Sale (S): 27,649 @ $36.23 · Sale (S): 851 @ $36.78 · Option exercise (M): 28,500 (derivative) @ $0 | EDGAR |
| 2024-05-31 | 4 | Morrison Scott W — Director | Grant/award (A): 16,200 (derivative) @ $0 | EDGAR |
| 2024-05-31 | 4 | MACKEY CATHERINE J — Director | Grant/award (A): 16,200 (derivative) @ $0 | EDGAR |
| 2024-05-31 | 4 | Kelley Susan L. — Director | Grant/award (A): 16,200 (derivative) @ $0 | EDGAR |
| 2024-05-31 | 4 | Stein Jeffrey — Director | Grant/award (A): 16,200 (derivative) @ $0 | EDGAR |
| 2024-05-31 | 4 | ROSEN TERRY J — Director | Grant/award (A): 16,200 (derivative) @ $0 | EDGAR |
| 2024-05-31 | 4 | YARNO WENDY L — Director | Grant/award (A): 16,200 (derivative) @ $0 | EDGAR |
| 2024-05-16 | 4 | Hata Yujiro S — President and CEO, Director | Option exercise (M): 56,711 @ $4.31 · Sale (S): 54,408 @ $41.60 · Sale (S): 2,303 @ $41.84 · Option exercise (M): 83,856 @ $4.31 · Sale (S): 53,592 @ $42.57 · Sale (S): 29,761 @ $43.48 · +7 more | EDGAR |
| 2024-03-04 | 4 | Ruiz Briseno Andres — See Remarks | Grant/award (A): 85,000 (derivative) @ $0 | EDGAR |
| 2024-03-04 | 4 | WHITE MICHAEL ANTHONY — Chief Scientific Officer | Grant/award (A): 140,000 (derivative) @ $0 | EDGAR |
| 2024-03-04 | 4 | Throne Jason — Chief Legal Officer | Grant/award (A): 125,500 (derivative) @ $0 | EDGAR |
| 2024-03-04 | 4 | Hata Yujiro S — President and CEO, Director | Grant/award (A): 480,000 (derivative) @ $0 | EDGAR |
| 2024-03-04 | 4 | Beaupre Darrin — Chief Medical Officer | Grant/award (A): 160,000 (derivative) @ $0 | EDGAR |
| 2024-02-13 | 4 | Ruiz Briseno Andres — See Remarks | Sale (S): 2,000 @ $46.02 | EDGAR |
| 2024-02-12 | 4 | Hata Yujiro S — President and CEO, Director | Option exercise (M): 75,815 @ $4.31 · Sale (S): 75,815 @ $45.15 · Option exercise (M): 23,557 @ $4.31 · Sale (S): 23,557 @ $45.54 · Option exercise (M): 75,815 (derivative) @ $0 · Option exercise (M): 23,557 (derivative) @ $0 | EDGAR |
| 2024-02-05 | 4 | Hata Yujiro S — President and CEO, Director | Option exercise (M): 628 @ $4.31 · Sale (S): 624 @ $45 · Sale (S): 4 @ $45.01 · Option exercise (M): 628 (derivative) @ $0 | EDGAR |
| 2024-01-24 | 4 | Ruiz Briseno Andres — See Remarks | Sale (S): 2,000 @ $42.03 | EDGAR |
| 2024-01-17 | 4 | Ruiz Briseno Andres — See Remarks | Sale (S): 2,000 @ $38.01 | EDGAR |
| 2024-01-17 | 4 | Hata Yujiro S — President and CEO, Director | Option exercise (M): 12,261 @ $4.31 · Sale (S): 12,261 @ $40.04 · Option exercise (M): 62,739 @ $4.31 · Sale (S): 62,739 @ $40.17 · Option exercise (M): 12,261 (derivative) @ $0 · Option exercise (M): 62,739 (derivative) @ $0 | EDGAR |
Recent 8-K events — IDEAYA Biosciences, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-04 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-23 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders 8.01 — Other Events | EDGAR |
| 2026-06-10 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-03 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-06-01 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-05 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-05 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-13 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-04-09 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-02-17 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=IDYA returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →